<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1617">
  <stage>Registered</stage>
  <submitdate>4/07/2007</submitdate>
  <approvaldate>4/07/2007</approvaldate>
  <nctid>NCT00497458</nctid>
  <trial_identification>
    <studytitle>Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects</studytitle>
    <scientifictitle>Phase II Study of Testosterone Replacement in Women Experiencing Aromatase Inhibitor Side-Effects in Adjuvant Therapy for Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym>ART2</trialacronym>
    <secondaryid>ART2</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <healthcondition>Arthralgia</healthcondition>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone

Placebo Comparator: Arimidex - Arimidex 1 mg plus placebo

Active Comparator: Arimidex test 40mg - Arimidex 1mg and testosterone 40mg

Active Comparator: Arimidex plus test 80mg - Arimidex 1mg and testosterone 80mg


Treatment: drugs: Testosterone
testosterone 40 or 80 mg once a day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduces arthralgia and associated joint symptoms as indicated by the change in hand or large joint pain from baseline to 3 months using a 100mm visual analogue scale for pain.</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Has acceptable safety and tolerability profile with particular reference to androgenic adverse events including acne, hirsutism, and alopecia.</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Impacts the bone resorption marker CTx</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Impacts serum HDL, LDL Trg, total Chol,</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Impacts serum levels of oestrogens, androgens and SHBG levels</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of written informed consent

          -  Undergone a total mastectomy, a lumpectomy or a quadrantectomy for primary breast
             cancer +/-chemo, +/-radiotherapy

          -  Have commenced anastrozole therapy within the previous 6 months

          -  Presence of node negative or positive disease

          -  Receptor-positive tumors, defined as ER =10% of the tumor cells positive by
             immunocytochemical evaluation

          -  Postmenopausal whether induced by surgery, radiotherapy (chemotherapy-induced
             amenorrhea may be difficult to determine they may be amenorrhoeic but still have
             functioning ovaries), or by being naturally amenorrhoeic, for 1 year or more if
             younger than 50 and for 6 months if 50 or older

          -  Postmenopausal levels of FSH/LH/E2 (follicle stimulating hormone, luteinizing hormone,
             oestrogen) according to the definition of "postmenopausal range" for the laboratory
             involved

          -  Have developed arthralgia and associated joint symptoms whilst being treated with
             anastrozole with a score of 40mm or greater on a pain and stiffness 100mm VAS

          -  WBC = 3.0 x 109/L, granulocytes = 1.5 X 109/L and platelets = 100 x 109/L.

          -  AST/SGOT or ALT/SGPT = 3 times ULN Serum creatinine = 2 times ULN</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence of metastatic disease

          -  Diabetes mellitus or glucose intolerance defined as a fasting glucose &gt;6mmol/l

          -  Previous or concomitant other (non-breast cancer) malignancy within the previous 5
             years

          -  Presence of other non-malignant systemic diseases which may prevent prolonged
             follow-up

          -  History of coronary artery disease or no history of previous coronary heart disease
             but at least two other coronary heart disease risk factors: LDL =8.8 mg/dL OR if fewer
             than two other coronary heart disease risk factors: LDL =10.45 mg/dL or total fasting
             cholesterol = 13.2 mg/dL

          -  Patients on hormone replacement therapy (HRT) within 4 weeks before trial treatment
             was initiated

          -  Patients on breast cancer chemoprevention with anti-oestrogens if less than 18 months
             between stopping and diagnosis of breast cancer

          -  Are at risk of transmitting Human Immunodeficiency Virus or viral hepatitis via
             infected blood

          -  Known hypersensitivity to any component of testosterone

          -  Unable to comply with study requirements

          -  Taking the following concomitant medications at the screening visit-bisphosphonate,
             anti-cancer treatment other than anastrozole (this includes Herceptin).

          -  Prolonged systemic corticosteroid treatment, except for topical applications (e.g. for
             rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local
             injections (e.g. intra-articular). Note: Short duration (&lt; 2 weeks) of systemic
             corticosteroids is allowed (e.g. for Chronic Obstructive Pulmonary Disease) but not
             within 1 month prior to randomisation.

          -  Any investigational drugs

          -  Systemic hormone replacement therapy

          -  Pregnant or lactating women

          -  Patients with history of fragility fracture or low BMD, osteoporosis or osteopenia

          -  Known liver disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2009</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Burnside Breast Centre - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Havah Therapeutics Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>AstraZeneca</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate whether increasing blood levels of androgen can
      reduce some of the side-effects of anti-estrogen therapy (Arimidex)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00497458</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen N Birrell, MD PhD</name>
      <address>Havah Therapeutics Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>